Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 396 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Schedule C Clear all
Completed Phase 1Phase 2 Interventional

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

NCT02206425
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Prednisone, Cyclophosphamide, Dexamethasone, Ascorbic acid, PLD, Lenalidomide, Pomalidomide
Drug · Dietary Supplement
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Bakersfield, California • Concord, California • Encinitas, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

NCT01610999
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma
Interventions
Plerixafor
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

NCT02387125
View directory record Official record
Conditions
Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
Interventions
CMB305, G100, Metronomic CPA
Biological · Drug
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Results available

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

NCT00062868
View directory record Official record
Conditions
Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
Interventions
LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C), LMP2 CTLs (ALSCER - Group A), LMP2 CTLs (ALSCER - Group B), LMP2 CTLs (ALSCER - Group C), LMP1/2 CTLs (ALCI - Expansion - Group A), LMP1/2 CTLs (ALCI - Expansion Group B), LMP1/2 CTLs (ALCI - Expansion Group C)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

NCT02386826
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
Interventions
INC280, bevacizumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 8:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Physiology of Human Brown Adipose Tissue

NCT04352244
View directory record Official record
Conditions
Adipose Tissue, Brown, Adipose Tissue, Obesity
Interventions
Fat biopsy, Blood sampling, Blood sample for DNA analysis
Procedure · Diagnostic Test · Genetic
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

NCT05557292
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
RMC-5552
Drug
Lead sponsor
Nicholas Butowski
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Recruiting Phase 1 Interventional

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
FT836, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

NCT01656642
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention

NCT03706742
View directory record Official record
Conditions
Hepatitis C, HepatoCellular Carcinoma
Interventions
Mailed outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
53 Years to 74 Years
Enrollment
12,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Family-Based Approaches to Improve Healthy Eating for Southeast Asian Children

NCT05817838
View directory record Official record
Conditions
Diet, Healthy
Interventions
Financial Incentives, Financial Incentives and Multilevel Multicomponent, School Engagement
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
6 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Comparing Strategies for Translating Self-management Support Into Primary Care

NCT01945918
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Self-management support education, Connection to Health Interactive Behavior Change Technology, Connection to Health plus Coaching (CTH+C)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 89 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Experiment of Sleep Technology

NCT04246424
View directory record Official record
Conditions
Sleep
Interventions
Fibit + Coaching, Coaching, Fitbit
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Mavorixafor, Ibrutinib
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG (Gamunex-C) Treatment Study for POTS Subjects

NCT03919773
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
IVIG, Albumin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 8:24 AM EDT
Recruiting Not applicable Interventional

Effects of Myoelectric Channel Count and Targeting for Upper Limb Prosthetic Control

NCT07011420
View directory record Official record
Conditions
Amputation, Amputation, Traumatic, Amputation, Congenital, Prosthesis User, Upper Limb Amputation Below Elbow (Injury), Amputation; Traumatic, Arm: Forearm, Between Elbow and Wrist
Interventions
Experimental socket with 4 untargeted channels active, Experimental socket with 8 untargeted channels active, Experimental socket with up to 16 untargeted channels active, Experimental socket with 8 targeted channels active, Coapt EMG Cuff
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Holliston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

NCT01321346
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Panobinostat, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Support for Caregivers of Older Adults With Cognitive Decline

NCT04787068
View directory record Official record
Conditions
Caregiver Burden, Depression, Confidence, Self, Cognition, Fatigue, Function
Interventions
Occupational Therapy support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Parent Training for Parents of Toddlers Born Very Premature:

NCT05217615
View directory record Official record
Conditions
Parenting, Problem Behavior, Premature Birth, Parenting Intervention
Interventions
ezParent, Coaching calls, Active Control
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
20 Months and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 8:24 AM EDT
Recruiting Not applicable Interventional

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

NCT05471908
View directory record Official record
Conditions
Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Interventions
As-needed follow up, Automatic follow-up
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Enrollment
2,674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Mountain View, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer

NCT00100672
View directory record Official record
Conditions
Neoplasms
Interventions
LErafAON-ETU
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 21, 2026, 8:24 AM EDT